Journal
SEMINARS IN ONCOLOGY
Volume 41, Issue 5, Pages 589-612Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.seminoncol.2014.07.003
Keywords
-
Categories
Funding
- Department of Defense [PR111043]
- National Cancer Institute [CA106450, CA161978]
- Enid A Haupt Endowed Chair
- Kids Walk for Kids with Cancer NYC
- Katie's Find a Cure Foundation
- Catie Hoch Foundation
- Robert Steel Foundation
Ask authors/readers for more resources
Ganglioside GD2 is a tumor-associated surface antigen found in a broad spectrum of human cancers and stem cells. They include pediatric embryonal tumors (neuroblastoma, retinoblastoma, brain tumors, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma), as well as adult cancers (small cell lung cancer, melanoma, soft tissue sarcomas). Because of its restricted normal tissue distribution, GD2 has been proven safe for antibody targeting. Anti-GD2 antibody is now incorporated into the standard of care for the treatment of high-risk metastatic neuroblastoma. Building on this experience, novel combinations of antibodies, cytokines, cells, and genetically engineered products all directed at GD2 are rapidly moving into the clinic. In this review, past and present immunotherapy trials directed at GD2 will be summarized, highlighting the lessons learned and the future directions. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available